Publications by authors named "A Moldenhauer"
New SARS-CoV-2 lineages continue to evolve and may exhibit new characteristics regarding host cell entry efficiency and potential for antibody evasion. Here, employing pseudotyped particles, we compared the host cell entry efficiency, ACE2 receptor usage, and sensitivity to antibody-mediated neutralization of four emerging SARS-CoV-2 lineages, KP.2, KP.
View Article and Find Full Text PDFArticle Synopsis
- Human-to-human transmission of MERS-CoV is inefficient, but there are worries it could mutate and become more transmissible.
- A study examined if enhancing the S1/S2 cleavage site of the MERS-CoV spike protein could improve its entry into human lung cells, similar to SARS-CoV-2.
- Results showed that changes to the cleavage site did not increase MERS-CoV's ability to infect lung cells, indicating it might not have the same transmission potential as SARS-CoV-2.
In July/August 2023, the highly mutated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BA.2.86 lineage emerged and its descendant JN.
View Article and Find Full Text PDFBackground And Objectives: Initial therapeutic efforts to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) included the use of plasma from convalescent donors containing anti-SARS-CoV-2 antibodies. High-neutralizing antibody titres are required for therapeutic efficacy. This study aims to show that immunoadsorption followed by tangential flow filtration can be used to obtain antibody concentrates with high-neutralizing capacities.
View Article and Find Full Text PDFBA.2.86, a recently identified descendant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.
View Article and Find Full Text PDF